• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Hemispherx Biopharma to Host Conference Call to Review Company's Accomplishments, Update on Influenza Related Studies and Outline Future Goals

Posted on: Tuesday, 11 April 2006, 09:01 CDT

Hemispherx Biopharma, Inc. ("Hemispherx" or the "Company") (AMEX: HEB) will hold a telephone conference call at 10:00 a.m. ET on Thursday, April 13, 2006 to review the Company's accomplishments, update on influenza related studies and outline future goals.

Dr. William A. Carter, Chairman & CEO, will host the call, which will include a management discussion followed by questions and answers. Robert Peterson, Chief Financial Officer, Doug Hulse, President and COO, and Dr. David Strayer, Medical Director, will also participate in the call.

Hemispherx invites stakeholders interested in hearing management's discussion to join the call by dialing 1-800-346-7359. International callers may access the call by dialing 973-528-0008. Participants will be asked to provide a conference entry code (CED) which is 410653. A replay of the conference call will be available through May 6, 2006 and can be accessed by dialing 1-800-332-6854 for domestic participants and 973-973-528-0005 for international participants. Participants for the replay will be asked to provide the conference entry code which is 410653.

About Hemispherx Biopharma

Hemispherx Biopharma, based in Philadelphia, is a biopharmaceutical company engaged in the manufacture and clinical development of new drug entities for treatment of viral and immune-based chronic disorders. Hemispherx Biopharma's flagship products include Alferon(R) and the experimental immunotherapeutics/antivirals Ampligen(R) and Oragens(TM). Alferon(R) is approved for a category of STD infection, and Ampligen(R) and Oragens(TM) represent experimental nucleic acids being developed for globally important viral diseases and disorders of the immune system. Hemispherx's platform technology includes large and small agent components for potential treatment of various chronic viral infections. Hemispherx has in excess of 100 patents comprising its core intellectual property estate, a fully commercialized product (Alferon(R) N) and GMP certified manufacturing facilities for its novel pharma products. For more information please visit www.hemispherx.net

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Any specifically referenced investigational drugs and associated technologies of the company (including Ampligen(R), Alferon(R) LDO and Oragens) are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements. Clinical trials for other potential indications of the approved biologic Alferon(R) do not imply that the product will ever be specifically approved commercially for these other treatment indications.

Source: Business Wire

More News in this Category